The U.S. Food and Drug Administration Approves Zanubrutinib (Brukinsa, BeiGene USA, Inc.) with Obinutuzumab for Relapsed/Refractory Follicular Lymphoma (FL)
Latest News On March 7, 2024, the U.S. Food and Drug Administration (FDA) announced it has approved Bruton tyrosine kinase inhibitor (BTKi), zanubrutinib